Factors Driving the Choice of the Best Second-Line Treatment of Advanced NSCLC

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|6|1|44-51

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.6, Iss.1, 2011-01, pp. : 44-51

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Second-Line Treatment of Advanced Gastric Cancer with Oxaliplatin plus Raltitrexed

By  

Oncology Research and Treatment, Vol. 26, Iss. 3, 2003-07 ,pp. : 255-258

Karger

Access to resources Recommend Favorite

Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers

By  

Oncology, Vol. 76, Iss. 4, 2009-02 ,pp. : 254-261

Karger

Access to resources Recommend Favorite

A Pilot Study of Docetaxel and Trofosfamide as Second-Line ‘Metronomic’ Chemotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

By  

Oncology Research and Treatment, Vol. 31, Iss. 4, 2008-03 ,pp. : 185-189

Karger

Access to resources Recommend Favorite

Second-Line Chemotherapy in Advanced Bladder Cancer

By  

Urologia Internationalis, Vol. 64, Iss. 2, 2000-05 ,pp. : 61-69

Karger

Access to resources Recommend Favorite

Imatinib Mesylate for Palliative Second-Line Treatment of Advanced Biliary Tract Cancer: A Bicentric Phase II Study

By  

Oncology Research and Treatment, Vol. 34, Iss. 8-9, 2011-08 ,pp. : 469-470

Karger

Access to resources Recommend Favorite